Evidence map›Paper›PMID 38011551›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation.

Virginia-Maria Vlachava, Sepehr Seirafian, Ceri A Fielding, Simon Kollnberger, Rebecca J Aicheler, Joseph Hughes, Alexander Baker, Michael P Weekes, Simone Forbes, Gavin W G Wilkinson and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. The immune response to human cytomegalovirus: impact of age, co-morbidities and the significance of anti-viral activity assessment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  6. Programmed cell death in triple-negative breast cancer.Cellular & molecular biology letters · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Evolution of theVirus evolution · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Virginia-Maria VlachavaInfection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Sepehr SeirafianInfection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0009-0000-8716-6123
Ceri A FieldingInfection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-5817-3153
Simon KollnbergerInfection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Rebecca J AichelerDepartment of Biomedical Sciences, Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff CF5 2YB, United Kingdom.
Joseph HughesCentre for Virus Research, School of Infection & Immunity, Glasgow University, Glasgow G61 1QH, United Kingdom.ORCID 0000-0003-2556-2563
Alexander BakerInfection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Michael P WeekesCambridge Institute for Medical Research, Department of Medicine, University of Cambridge, Cambridge CB2 0XY, United Kingdom.ORCID 0000-0003-3196-5545
Simone ForbesInfection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Gavin W G WilkinsonInfection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Eddie C Y Wang *Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-2243-4964
Richard J Stanton *Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-6799-1182
Cardiff University · GBCardiff Metropolitan University · GBMRC University of Glasgow Centre for Virus Research · GBUniversity of Cambridge · GB

Funding

Medical Research Council MR/P001602/1Medical Research Council MR/S00971X/1Medical Research Council MR/V000489/1Medical Research Council MR/W025647/1Wellcome Trust
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a paradigm of pathogen immune evasion and sustains lifelong persistent infection in the face of exceptionally powerful host immune responses through the concerted action of multiple immune-evasins. These reduce NK cell activation by inhibiting ligands for activating receptors, expressing ligands for inhibitory receptors, or inhibiting synapse formation. However, these functions only inhibit direct interactions with the infected cell. To determine whether the virus also expresses soluble factors that could modulate NK function at a distance, we systematically screened all 170 HCMV canonical protein-coding genes. This revealed that UL4 encodes a secreted and heavily glycosylated protein (gpUL4) that is expressed with late-phase kinetics and is capable of inhibiting NK cell degranulation. Analyses of gpUL4 binding partners by mass spectrometry identified an interaction with TRAIL. gpUL4 bound TRAIL with picomolar affinity and prevented TRAIL from binding its receptor, thus acting as a TRAIL decoy receptor. TRAIL is found in both soluble and membrane-bound forms, with expression of the membrane-bound form strongly up-regulated on NK cells in response to interferon. gpUL4 inhibited apoptosis induced by soluble TRAIL, while also binding to the NK cell surface in a TRAIL-dependent manner, where it blocked NK cell degranulation and cytokine secretion. gpUL4 therefore acts as an immune-evasin by inhibiting both soluble and membrane-bound TRAIL and is a viral-encoded TRAIL decoy receptor. Interestingly, gpUL4 could also suppress NK responses to heterologous viruses, suggesting that it may act as a systemic virally encoded immunosuppressive agent.

Indexed as

CytomegalovirusKiller Cells, NaturalApoptosisGlycoproteinsHumansImmune EvasionGlycoproteinsHCMVNK CellsTRAIL

Identifiers

PMID38011551
PMCPMC10710050
OpenAlexW4389040488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.